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Abstract
Multiple Sclerosis (MS) is the most common cause of acquired neurological disability in young adults, pathologically
characterized by leukocyte infiltration of the central nervous system, demyelination of the white and grey matter, and
subsequent axonal loss. Microglia are proposed to play a role in MS lesion formation, however previous literature has
not been able to distinguish infiltrated macrophages from microglia. Therefore, in this study we utilize the microglia-
specific, homeostatic markers TMEM119 and P2RY12 to characterize their immunoreactivity in MS grey matter lesions
in comparison to white matter lesions. Furthermore, we assessed the immunological status of the white and grey
matter lesions, as well as the responsivity of human white and grey matter derived microglia to inflammatory
mediators. We are the first to show that white and grey matter lesions in post-mortem human material differ in their
immunoreactivity for the homeostatic microglia-specific markers TMEM119 and P2RY12. In particular, whereas
immunoreactivity for TMEM119 and P2RY12 is decreased in the center of WMLs, immunoreactivity for both markers is
not altered in GMLs. Based on data from post-mortem human microglia cultures, treated with IL-4 or IFNγ+LPS and
on counts of CD3+ or CD20+ lymphocytes in lesions, we show that downregulation of TMEM119 and P2RY12
immunoreactivity in MS lesions corresponds with the presence of lymphocytes and lymphocyte-derived cytokines
within the parenchyma but not in the meninges. Furthermore, the presence of TMEM119+ and partly P2RY12+
microglia in pre-active lesions as well as in the rim of active white and grey matter lesions, in addition to TMEM119+
and P2RY12+ rod-like microglia in subpial grey matter lesions suggest that blocking the entrance of lymphocytes into
the CNS of MS patients may not interfere with all possible effects of TMEM119+ and P2RY12+ microglia in both white
and grey matter MS lesions.
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Introduction
Multiple Sclerosis (MS) is the most common cause of ac-
quired neurological disability in young adults. It is a chronic
inflammatory, degenerative disease of the central nervous
system (CNS), pathologically characterized by leukocyte in-
filtration of the CNS, demyelination of the white and grey
matter, and subsequent axonal loss. From a clinical point of
view, MS is very heterogeneous and is associated with an
array of symptoms, including sensory and motor deficits,
fatigue, cognitive and psychiatric disturbances [1, 2].
Microglia are considered to play an important role in
MS lesion formation [3–7]. Dysfunction of the blood-
brain-barrier leads to infiltration of leukocytes into the
CNS, possibly attracted by antigens presented by micro-
glia and/or by infiltrated macrophages [6, 8]. Indeed, ac-
tivated, amoeboid-shaped microglia are present within
active white matter lesions (WMLs) and in the rim of
chronic-active WMLs, expressing MHC-II [9]. Pre-active
lesions consisting of microglial nodules expressing
MHC-II can also be found in the normal appearing
white-matter, preceding demyelination and infiltration
of leukocytes [10].
When studying the expression profile of microglia, at
least two genes have been related to a homeostatic sig-
nature of microglia in the human and rodent brain, i.e.
TMEM119 and P2RY12. Both TMEM119 and P2RY12
mRNA have been shown to be expressed only by micro-
glia and not by infiltrating macrophages [11–14]. Inter-
estingly, TMEM119 and P2RY12 immunoreactivity has
been shown to be reduced in active WMLs compared to
normal-appearing WM in post-mortem MS patient
brain material which can indicate either a decrease in
microglia presence in the WML or regulation of the
microglia markers by the local inflammatory environ-
ment [15–17]. This last option is supported by observa-
tions that P2RY12 expression in human microglia is
enhanced by the anti-inflammatory cytokine interleukin-
4 (IL-4) [15, 18], whereas TMEM119 mRNA levels are
reduced in mouse derived microglia treated with pro-
inflammatory lipopolysaccharide in vitro [11], indicating
that expression of both markers can be regulated by in-
flammatory cytokines.
Contrary to WMLs, to date, there has been no study
on the expression of TMEM119 and P2RY12 in grey
matter lesions (GMLs). However, recent studies utilizing
single-cell RNA-seq have shown that microglia in nor-
mal appearing white matter (NAWM) and normal-
appearing grey matter (NAGM) of MS patients differ in
their gene expression pattern [19]. In line with this ob-
servation, it was already shown in normal rodent brain,
that microglia derived from various brain regions show a
region-specific expression profile [20, 21]. In that respect
it is worth noting that, different from WMLs, microglia
in MS GMLs only sparsely express MHC-II and show
mostly a ramified or ‘reactive’ phenotype instead of an
amoeboid, ‘active’ phenotype [22–24].
If we want to understand how microglia can contrib-
ute to MS lesion formation, more attention should be
focused on microglia in GMLs. In GMLs, demyelination
is as evident, or even more extensive [25–27] as in
WMLs, but the microglial and inflammatory response
appears different. Therefore, in order to expand the
existing literature we identified and compared the ex-
pression of the homeostatic markers TMEM119 and
P2RY12 in MS GMLs to WMLs. To this end, we used
post-mortem human MS brain material containing sub-
pial GMLs and various WML types, and leukocortical le-
sions to perform immunohistochemical analysis of
TMEM119 and P2RY12. Moreover, the immunological
status of the lesions was determined and the responsivity
of human white matter (WM) and grey matter (GM) de-
rived microglia to inflammatory mediators was assessed.
Methods
Post-mortem human brain tissue
Post-mortem brain material of MS patients was obtained
from the Netherlands Brain Bank (NBB, Amsterdam,
The Netherlands) and from the Biobank of the
Amsterdam MS center (Amsterdam, The Netherlands).
In compliance with all local ethical and legal guidelines,
informed consent for brain autopsy and the use of brain
tissue and clinical information for scientific research was
given by either the donor or the next of kin. For immu-
nohistochemical purposes, a total of 27 tissue blocks
from 18 clinically diagnosed and pathologically verified
MS patients were used. For isolating primary microglia,
fresh NAWM and NAGM tissue was taken at autopsy
from 12 patients with various neurological diseases.
Clinicopathological information of patients from which
brain material was used in this study, is provided in
Table 1.
Immunohistochemistry
After autopsy, dissected brain tissue was fixed in 4% for-
malin and subsequently embedded in paraffin. From the
obtained cortical and subcortical tissue paraffin blocks,
10 μm sections were cut on a microtome and mounted
on positively charged glass slides (Permafrost) and incu-
bated on a heated plate for 1 h at 43 °C. Afterwards,
slides were dried overnight in an incubator at 37 °C be-
fore being stored at room temperature (RT). Upon use
for immunohistochemistry, tissue sections were heated
to 58 °C for 30 min. Subsequently, sections were deparaf-
finized in xylene replacement (100%) and graded ethanol
series (100, 96, 80 and 70%) to demi-water. For antigen
retrieval, sections were heated to 90–95 °C in 10mM
Tris buffer containing 1mM EDTA (Tris-EDTA, pH 9)
or in 0.1M citrate buffer (pH 6, see Table 2) for 30 min.
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in a conventional steam cooker. When cooled down
to RT, sections were washed in TBS (pH 7.6) and
incubated in TBS with 1% H2O2 for 20 min. to
block endogenous peroxidase activity. Subsequently,
after washes with TBS, the sections were incubated
for 30 min. in TBS containing 0.5% Triton (TBS-T)
and 5% milk powder (Campina, Zaltbommel, The
Netherlands; block buffer) to block non-specific
antibody binding.
Primary antibodies were diluted in block buffer as in-
dicated in Table 2, and the sections were incubated with
the antibodies overnight at 4 °C. Then, sections were
washed in TBS and incubated in block buffer containing
corresponding biotinylated goat anti mouse IgGs (1:400,
Table 1 Clinicopathological information of included patients for immunohistochemistry and primary microglia isolation
Patient Age Gender Diagnosis Disease duration *
(years)
Post-mortem delay
(h)
Cause of death Lesions
Immunohistochemistry
1 60 M SPMS 16 8:49 Euthanasia 1 aWML, NAWM, NAGM
2 48 M PPMS 18 6:35 Dehydration 2 aWML, 2 cWML, 2 sGML,
NAWM, NAGM
3 66 F PPMS 27 9:45 Pneumonia 1 sGML, NAWM, NAGM
4 52 F PPMS 25 8:40 Euthanasia 1 cWML, 1 sGML, NAWM, NAGM,
5 74 F PPMS 16 10:30 Respiratory failure 1 sGML, NAWM, NAGM,
6 65 F SPMS 22 10:45 Brain infarction 2 cWML, 1 sGML, NAWM, NAGM,
7 66 F SPMS 22 6:00 Unknown 2 aWML, 1 sGML, NAWM, NAGM
8 51 M SPMS 20 11:00 Unknown 2 aWML, 1 cWML, NAGM
9 50 F SPMS 12 9:05 Euthanasia 1 aWML, 1 sGML, NAWM,
10 50 M SPMS 21 10:50 Euthanasia 1 aWML, NAWM, NAGM
11 54 M PPMS 12 8:15 Euthanasia 1 cWML,1 sGML
12 54 F SPMS 23 9:25 Respiratory failure 1 aWML
13 47 F SPMS 27 8:35 Pneumonia 1 aGML
14 53 M PPMS 2 5:30 Pneumonia 1 leukocortical lesion
15 41 F SPMS 11 8:25 Natural causes 1 leukocortical lesion
16 45 M SPMS 20 7:45 Cardiac Arrest 1 leukocortical lesion
17 54 F SPMS 24 9:10 Dyspnea followed by
palliative care
1 leukocortical lesion
18 57 F SPMS 25 10:40 Euthanasia 1 leukocortical lesion
Primary microglia isolation
15 81 M PD 38 8:05 Septic Shock
16 65 M SPMS 34 9:30 Euthanasia
17 51 F SPMS 17 9:10 Euthanasia
18 70 M SPMS 33 9:25 Euthanasia
19 81 F PD 7 10:50 Respiratory Failure
20 76 F Hypokinesia /
PD
9 9:15 Heart Failure
21 67 F PPMS 16 5:45 Euthanasia
22 35 F Neuropathic
pain
8 5:20 Euthanasia
23 65 F MSA-P 3 7:05 Euthanasia
24 67 M PPMS 11 7:55 Euthanasia
25 52 F PPMS 2 9:30 Euthanasia
26 83 F PPMS 34 7:40 Ovarian Cancer
M male, F female, SP Secondary progressive, PP Primary progressive, PD Parkinson’s Disease, MSA-P Multiple System Atrophy-Parkinsonism, * Starting from first
diagnosis, NAGM normal appearing grey matter, NAWM normal appearing white matter, cWML chronic white matter lesion, aWML active white matter lesion, sGML
subpial grey matter lesion, aGML active grey matter lesion
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Jackson laboratories, Cambridge, UK) or biotinylated
donkey anti rabbit IgGs (1:400, Jackson laboratories) at
RT for 2 h. Subsequently, sections were washed in TBS
and incubated for 1 h with horseradish peroxidase-
labeled avidin-biotin complex (ABC complex, 1:400,
Vector Labs) in TBS-T at RT. Finally, after washes in
TBS and Tris-HCl, immunoreactivity was visualized by
adding 3,3-diaminobenzidine (DAB, Sigma, St. Louis,
USA) or NovaRED (Vector Labs, Peterborough, UK),
and sections were counterstained with hematoxylin. Sec-
tions were subsequently dehydrated in graded series of
ethanol, cleared in xylene and mounted with Entellan.
Identification of multiple sclerosis lesion types
MS lesion types were identified in post-mortem brain
material by immunohistological staining for myelin pro-
teolipid protein (PLP) and staining for the HLA-DR
marker MHC-II. Lesion location was determined by the
relative absence of PLP immunoreactivity indicating de-
myelinating/demyelinated areas. WML types were classi-
fied according to Kuhlmann et al. (2017) [9]. WML
types were characterized as active when immunoreactiv-
ity for PLP was lost and a large number of amoeboid
MHC-II+ cells was present in the demyelinating or
demyelinated lesion (Fig. 1a, b). WMLs showing a ‘rim’
of MHC-II+cells around the demyelinated lesion with
less, but still apparent amoeboid MHC-II+ cells in the
center of the demyelinated lesion were deemed chronic-
active WMLs (or mixed active/inactive according to
Kuhlmann et al., (2017) (Fig. 1c, d). In contrast to
WMLs, characterization of lesions in the GM is based
on location rather than MHC-II+ activity [28]. Lesions
showing loss of myelin (as indicated by reduced PLP
staining) from the outer layer into the cortex were
deemed subpial lesions [9, 29]. They often present with
little MHC-II+ cells (Fig. 1g, h) [23]. Lesion activity in
GMLs is defined by the presence or absence of a rim of
activated microglia surrounding the lesion area as
defined by Peterson et al., (2001) [30]. One case showed
a subpial GML with a clear rim of activated MHC-II+
cells, this lesion was deemed an active subpial GML
(Fig. 1e, f) [23]. Type 1 (leukocortical) lesions featured a
chronic-active white-matter demyelinated area, charac-
terized by a rim of MHC-II+ cells and a grey-matter
demyelinated area with a comparatively low amount of
MHC-II+ cells similar to subpial GMLs (Additional file 1:
Figure S1) [9]. In addition, WM areas with MHC-II+ micro-
glial nodules, but no demyelination and not in close prox-
imity to blood vessels were deemed pre-active lesions [10].
Double-labeling immunohistochemistry
Sections were pretreated as described for single labeling
above. Sections were incubated overnight at 4 °C with
both primary antibodies (either TMEM119, P2RY12 or
Iba-1, for dilutions see Table 2) diluted in block buffer.
Sections were washed in TBS and incubated with alka-
line phosphatase ImmPRESS anti-Rabbit IgG polymer
detection kit (Vectorlabs) for 30 min. at RT. Subse-
quently, slides were washed again and incubated for 2 h
at RT with a biotinylated donkey anti goat IgG’s (Iba-1;
1:400, Jackson laboratories). Subsequently, sections were
washed in TBS and incubated for 1 h at RT with horse-
radish peroxidase labeled avidin-biotin complex (ABC
complex, 1:400 Vectashield). Afterwards, slides were
washed in TBS and immunoreactivity of TMEM119 or
P2RY12 was then visualized by adding Liquid Permanent
Red (LPR, DAKO) and Iba-1 immunoreactivity was visu-
alized using the Vector SG Peroxidase kit (Vectorlabs).
Subsequently, sections were washed and dried on a
heated plate at 37 °C before being cleared in xylene and
mounted with Entellan.
Separation of color signals from double-labeled sections
Pictures of double labeled sections were taken at wave-
lengths ranging from 480 nm to 680 nm at 60x magnifi-
cation using the Nuance multispectral imaging system
Table 2 Primary antibodies used for immunohistochemistry
Primary antibody Ab Dilution Antigen Retrieval Source (article number)
Rabbit anti TMEM119 C-terminus 1:500 Tris/EDTA pH 9 Atlas Antibodies, Sweden (HPA051870)
Rabbit anti Human P2Y12R C-terminus 1:200 Tris/EDTA pH 9 Anaspec, Netherlands (AS-55042A)
Mouse anti MHC-II (HLA-DR) 1:1000 Tris/EDTA pH 9 Clone LN3, Pierce, ThermoFisher (MA5–11966)
Rabbit anti Iba-1 1:1000 Citrate pH 6 WAKO Chemicals U.S.A. (019–19,741)
Mouse anti PLP 1:250 Tris/EDTA pH 9 Serotec (MCA839G)
Rabbit anti CD3 1:100 Citrate pH 6 DAKO, Denmark (A04520)
Mouse anti CD20 1:200 Tris/EDTA pH 9 DAKO, Denmark (M0755)
Mouse anti IL-4 1:500 Citrate pH 6 BioMatik (CAU29167)
Mouse anti IFN-γ 1:000 Tris/EDTA pH 9 Abcam, U.K. (ab218426)
Goat anti Iba-1 1:500 Tris/EDTA pH 9 Abcam, U.K. (ab5076)
Ab antibody
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(PerkinElmer). LPR stained cells and Vector SG stained
cells were separated based on their light emission which
yields images similar to fluorescently labeled antibodies.
Using the open source software ImageJ [31], composi-
tions of the separated signals were then made to
visualize co-localization.
Fig. 1 Representative images of lesion types used in this study. Lesions are characterized by loss of PLP staining and amount of MHC-II+ cells. A
large amount of of MHC-II+ cells can be observed in the demyelinated area (a) in active WMLs (b). Chronic-active demyelinated WMLs (c) feature
a ‘rim’ of MHC-II cells (d) which is also visible in demyelinated active GMLs (e, f). Subpial demyelinated (g) GMLs hardly show MHC-II+ cells (h).
Scalebar (a-h) = 200 μm. Dashed lines indicate the edge of the lesion
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Semi-quantitative analysis of immunoreactivity
Immunoreactivity detected in active and chronic-active
WMLs, NAWM, subpial GMLs and NAGM was ana-
lyzed using ImageJ. Per lesion, depending on the lesion
size, 1–2 images were made at 20x magnification using a
Leica DM5000B microscope. Per NAWM and NAGM
area, 2 images were made. All images analyzed had a re-
gion of interest (ROI) of 622 × 466 μm. Within these
ROIs, signals from DAB and hematoxylin were separated
using the color deconvolution plug-in [32]. From the
subsequently acquired DAB images without heamatoxy-
lin signal, an auto-threshold method was applied. The
measured area fraction (percentage of DAB stained area
per ROI) obtained when 2 images were taken, was aver-
aged. If one tissue block featured several lesions of the
same type, these values were averaged. If multiple tissue
blocks from the same patient featured the same lesion
types, measurements from these lesions were considered
separate independent values.
Cell counts were conducted using an Olympus BX45
microscope with a U-OCMSQ 10/10 eyepiece microm-
eter (Olympus Lifescience) featuring a square of 10 × 10
mm2. Cells positive for CD3, CD20, IL-4 or IFNγ in le-
sions or NAM were counted in three random squares of
10 × 10 mm2 at 20x magnification and counts were aver-
aged and expressed as number of positive cells/mm2.
Isolation, culture and treatment of primary human
microglia
Normal appearing human white and grey matter (5–10 g
per isolation) were obtained at autopsy and stored at
4 °C in medium consisting of equal amounts of Dulbec-
co’s Modified Eagle Medium (DMEM; Gibco, Life Tech-
nologies, Breda, The Netherlands) and Ham’s F12
nutrient mix (Gibco, Life Technologies, Breda, The
Netherlands) supplemented with 50 μg/ml gentamycin
(Invitrogen, Eugene, USA). Isolation of primary micro-
glia was conducted either directly after tissue collection
or within 12 h thereafter. Subsequently, tissue was
washed in collection medium and chopped using a ster-
ile razor blade. Tissue was trypsinized for 30 min at
37 °C using 0.25% trypsin (Difco) dissolved in a trypsini-
zation buffer (8 g/l NaCl (Sigma), 0.4 g/l KCl (Sigma,
Darmstadt, Germany), 0.84 g/l NaHCO3 (Merck, Darm-
stadt, Germany), 0.2 g/l EDTA (Promega, Madison,
USA), 4.8 g/l HEPES (Sigma), and 1 g/l glucose dissolved
in MilliQ water, pH set at 7.6). After incubation, culture
medium consisting of equal amounts of DMEM and
Ham’s F12 supplemented with 10% fetal calf serum
(Gibco, Life Technologies), 1% Penicillin/Streptomycin
(Invitrogen) and 1% L-glutamine (Invitrogen) was added
to de-activate the trypsin and the tissue homogenate was
further dissociated using titration with a 10 ml pipette
into a homogenous suspension which was filtered using
a 100 μm mesh (Greiner-bio-one, Alphen aan de Rijn,
The Netherlands). The suspension was centrifuged and
the cell pellet was resuspended in 30% Percoll diluted in
a gradient buffer (3.56 g/l of Na2HPO42H2O (Merck),
0.78 g/l of NaH2PO4H2O (Merck), 8 g/l of NaCl
(Merck), 4 g/l of KCl (Merck), 2.0 g/l of d-(+)-glucose,
and 2.0 g/l of BSA, pH 7.4) supplemented with 2.5%
NaCl (1.5 mol/l) (GE Healthcare Biosciences AB, Upp-
sala, Sweden). The suspended cells were subsequently
overlaid with the aforementioned gradient buffer and
centrifuged for 35 min at 450×g at 18 °C with no acceler-
ation or brake. After centrifugation, a myelin layer was
formed at the interphase and microglial cells are pel-
leted. This cell pellet was treated with erythrocyte shock
buffer (8.3 g/l of NH4Cl (Merck) and 1 g/l of KHCO3
(Merck), pH 7.4) for 15 min at 4 °C. Subsequently, cells
were centrifuged and the pellet resuspended in 7.2 ml
culture medium as described above and 600 μl cell sus-
pension/well was added to a 24 well plate coated with
15 μg/mL Poly-L-Lysine (Sigma). After one day of cul-
turing, cells were cultured in culture medium + 25 ng/ml
human recombinant granulocyte-macrophage colony-
stimulating factor (GM-CSF; Peprotech, London, the
UK). Medium was changed every three days by replacing
half of the medium with culture medium. After 7–10
days of culturing, cells were treated with recombinant
human interleukin (IL)-4 (10 ng/ml; Biolegend, San
Diego, USA) for 48 h or with recombinant human
interferon (IFN)γ (10 ng/ml; Biolegend) for 24 h
followed by addition of 10 ng/ml lipopolysaccharide
(LPS, derived from E.coli O55:B5; Difco) for 24 h [33]
or left untreated.
Semi-quantitative RT-PCR
Per treatment condition, 3–5 wells containing microglial
cells were lysed in a total of 1 ml TRIzol (Invitrogen). To
the combined sample, 200 μl chloroform was added and
tubes were centrifuged at 12,000×g for 15 min. at 4 °C.
After the phenol-chloroform-extraction, RNA was puri-
fied and cleaned up using the E.Z.N.A. MicroElute RNA
Clean Up kit (Omega Bio-Tek, Norcross, USA) and ana-
lyzed for quality and quantity using a NanoDrop spec-
trophotometer (Thermo Scientific). Input of RNA for
cDNA synthesis for all samples was normalized based
on the sample with the lowest concentration of RNA.
Per sample, 250 ng total RNA of sufficient quality (260/
230 ratio of ≥2 and 260/280 ratio ≥ 1.8) was reverse-
transcribed into cDNA using the High-Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Bleiss-
wijk, The Netherlands) with oligo-d(T) primers (50 μM,
Invitrogen) according to the manufacturer’s description.
Semi-quantitative RT-PCR was performed in a total vol-
ume of 10 μl per sample consisting of 3 μl of Power
SYBR Green Master Mix (Life Technologies, Carlsbad,
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USA), with 50 μM of each forward and reverse primers
(see Table 3), and 6 ng/μl cDNA in a MicroAmp Optical
96-well Reaction Plate (Applied Biosystems, Foster
city, USA). The PCR reaction was performed using
the StepOnePlus Real-Time PCR system (Applied
Biosystems). The PCR protocol was adapted from the
manufacturers description and featured 40 cycles with
an annealing temperature of 60 °C, followed by a
melt curve analysis. The relative expression level of
the target genes was determined by the LinReg PCR
software (version 2014 4.3 (July 2014); website:
http://www.hfrc.nl) using the following calculation
N0 = Nq/ECq (N0 = target quantity, Nq = fluorescence
threshold value, E = mean PCR efficiency per ampli-
con, Cq = threshold cycle). In total 7 housekeeping
genes were tested, of which SDHA and POLR2F ex-
pression were selected for gene expression
normalization using NormFinder [34]. Data analysis
was performed on the normalized N0 values.
Statistical analysis
Statistical analysis was conducted using SPSS Statis-
tics 22 (IBM, Armonk, USA). None of the semi-
automatically quantified DAB stained signal datasets
showed a normal distribution and were therefore ana-
lyzed using a Kruskall-Wallis test with pairwise com-
parisons, using the Bonferroni correction for multiple
testing. P-values < 0.05 were considered statistically
significant. Data from the semi-quantitative RT-PCR
also did not show a normal distribution. In order to
compare differences on a group level within WM- or
GM-derived conditions, a Friedman’s test was used
with post-hoc testing done manually by comparing in-
dividual data sets within WM- and GM-derived
microglia with the Wilcoxon Signed Ranks test. Dif-
ferences between GM and WM conditions were indi-
vidually compared with the Wilcoxon Signed Ranks
test, p values were adjusted with the Bonferroni
correction. P values < 0.05 were considered statisti-
cally significant.
Results
TMEM119 and P2RY12 immunoreactivity was absent in
WMLs but not in pre-active WMLs
Compared to NAWM, where MHC-II+ microglia
showed a ramified appearance (Fig. 2a), active WMLs
showed numerous amoeboid, MHC-II+ cells (Fig. 2b).
Chronic-active WMLs showed MHC-II+ cells with a
more reactive phenotype (Fig. 2c). Iba-1 showed a simi-
lar pattern of immunoreactivity as MHC-II+ cells
(Fig. 2d,e,f). In contrast, TMEM119+ cells were present
in ramified microglia in the NAWM (Fig. 2g), but its im-
munoreactivity was absent in active WMLs and chronic-
active WMLs (Fig. 2h, i). P2RY12+ cells were present in
ramified cells similarly to what was observed for MHC-
II+ and Iba-1+ cells in the NAWM (Fig. 2j), but they
were virtually absent in active WMLs. In contrast to
TMEM119, P2RY12 immunoreactivity reappeared in the
center of chronic-active WMLs, showing a reactive
phenotype similar to Iba-1 and MHC-II+ cells in those
lesions (Fig. 2k, l). In preactive WMLs which appeared
in white matter that showed no demyelination (Fig. 2m)
but did show MHC-II immunoreactivity (Fig. 2n),
TMEM119 (Fig. 2o) and P2RY12 (Fig. 2p) immunoreac-
tivity was present.
TMEM119 and P2RY12 immunoreactivity was present in
subpial GMLs
To verify that TMEM119 and P2RY12 were markers for
GM microglia in addition to WM microglia, we ob-
served that both markers completely overlap with Iba-1+
microglia in white- and grey normal appearing matter
(Additional file 1: Figure S2). Compared to NAGM,
where MHC-II immunoreactivity was present in a small
amount of ramified microglia, MHC-II+ microglia
showed a more reactive phenotype in the active subpial
GML (Fig. 3a, b). Subpial GMLs without an active rim
showed limited MHC-II immunoreactivity similar to
NAGM (Fig. 3c). Iba-1 immunoreactivity in the NAGM
was present in ramified microglia (Fig. 3d). Similar to
MHC-II immunoreactivity, active subpial GML showed
Iba-1 immunoreactivity in microglia with a more
Table 3 Primer sequences used for qPCR
Primer Primer sequence forward (5′- 3′) Primer sequence reverse (3′-5′)
TMEM119 TCCAGGGTCAGATTACAAGAGCAC ACTGTTGATTCTGGAGGGTTTGA
P2RY12 ACTCTCTCTTCCAGCCCAGGT CCAGGACCAGTTCCTTGGCGTA
AIF-1 CCCTCCAAACTGGAAGGCTTCA CTTTAGCTCTAGGTGAGTCTTGG
GFAP GCAGATTCGAGAAACCAGCC GCTCCTGCTTGGACTCCTTA
IL-1β TACAGCTGGAGAGTGTAGATC CAAATTCCAGCTTGTTATTG
MRC AGTGATGGGACCCCTGTAACG CCCAGTACCCATCCTTGCCTTT
SDHAa CCAGGGAAGACTACAAGGTGCGGA AGGGTGTGCTTCCTCCAGTGCT
POLR2Fa GAACTCAAGGCCCGAAAG TGATGATGAGCTCGTCCAC
a selected as housekeeping gene
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reactive phenotype (Fig. 3e) whereas Iba-1 immunore-
activity in less inflammatory subpial GMLs often was
visible in rod-like microglia (Fig. 3f). Immunoreactiv-
ity for TMEM119 was found in ramified microglia in
the NAGM (Fig. 3g), more reactive TMEM119+
microglia were present in active subpial GMLs
(Fig. 3h) and in rod-like microglia in subpial GMLs
(Fig. 3i). P2RY12 immunoreactivity was clearly present
in microglia in NAGM (Fig. 3j), in active subpial
GMLs (Fig. 3k) and in (rod-like) microglia in subpial
GMLs (Fig. 3l).
TMEM119 and P2RY12 microglial immunoreactivity is
decreased in WMLs, but not in subpial GMLs and
leukocortical GMLs
Semi-automatic quantification of the DAB stained area
for MHC-II, Iba-1, TMEM119 and P2RY12 was
conducted on all lesion types, including leukocortical
(type 1) lesions. The type 1 lesions were added to the
analysis to exclude that the differences in immunoreac-
tivity found between GMLs and WMLs were either due
to location, or due to time of lesion development. Ana-
lysis of MHC-II immunoreactivity revealed a significant
Fig. 2 Representative images of MHC-II (a, b, c), Iba-1 (d, e, f), TMEM119 (g, h, i) and P2RY12 (j, k, l) immunoreactivity in normal appearing matter
and in the demyelinated center of active WMLs and chronic-active WMLs and in pre-active lesions (m, n, o, p). Scalebars (a-l and m-p) = 50 μm
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difference between all lesion types (Fig. 4a, X2(6) =
49.459, p < 0.01). MHC-II immunoreactivity was sig-
nificant between NAWM and NAGM (p < 0.05) and
NAWM and active WML (p < 0.05, Fig. 4a). Iba-1
immunoreactivity was also significantly different be-
tween all lesion types (Fig. 4b, X2(6) = 21.202, p <
0.01). Post-hoc testing revealed a significant differ-
ence in immunoreactivity between chronic-active
WMLs and active WMLs (Fig. 4b, p < 0.05), likely
reflecting the decrease in cell numbers observed in
chronic-active WMLs compared to NAWM and ac-
tive WMLs. TMEM119 immunoreactivity showed sig-
nificant differences between lesion types (Fig. 4c,
X2(6) = 42.728, p < 0.01). Post-hoc testing revealed a
significant decrease in active WMLs (p < 0.01),
chronic-active WMLs (p < 0.01) and leukocortical
WMLs (p < 0.01) compared to NAWM. Similarly to
TMEM119, P2RY12 immunoreactivity showed signifi-
cant differences between lesion types (X2(6) = 31.705,
p < 0.01) primarily driven by differences between
NAWM and active WMLs (p < 0.01), and chronic ac-
tive WMLs (p < 0.05).
TMEM119 and P2RY12 immunoreactivity in the rim of
active subpial GMLs and the rim of active WMLs
appeared similar
MHC-II + cells and Iba1+ cells were present in the rim
of active WMLs, chronic-active WMLs and active sub-
pial GMLs (Fig. 5a-f). Even though immunoreactivity for
TMEM119 was absent in the center of active WMLs
(Fig. 2h), TMEM119 + cells were visible at the edge of
active WMLs and active subpial GML, but not in the
rim of chronic-active WMLs (Fig. 5g-i). P2RY12+ cells
were absent along the rim of active WMLs but present
in the rim of chronic-active WMLs (Fig. 5j-k), where im-
munoreactivity for P2RY12 was also visible in the center
of the lesion (Fig. 2l). Similar to the edge of active
WMLs, P2RY12+ cells were absent in the edge of active
subpial GMLs (Fig. 5l).
Fig. 3 Representative images of MHC-II (a, b, c), Iba-1 (d, e, f), TMEM119 (g, h, i) and P2RY12 (i, k,l) immunoreactivity in NAGM, active subpial
GMLs and non-active subpial GMLs. Arrows indicate rod-shaped microglia visible in subpial GMLs in Iba-1+ cells (f), TMEM119 + cells (i) and
P2RY12+ cells (l). Scalebar = 50 μm
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Regulation of TMEM119 and P2RY12 expression by pro-
or anti-inflammatory mediators in primary human
microglia
To determine whether the differences in microglial
TMEM119 and P2RY12 immunoreactivity between
WMLs and GMLs were due to differences in microglial
responsiveness, we isolated primary human microglia
from WM (corpus callosum) and GM (cortex) tissue ob-
tained at autopsy and treated those with IFNγ+LPS or
IL-4 as representatives of a pro- or anti-inflammatory
stimulus, respectively. Seven out of twelve patients from
which microglia were isolated were diagnosed with MS
(Table 1). The mRNA levels observed of various genes
expressed in microglia of these patients did not differ
from that of the five patients with other diagnoses (data
not shown). The levels of TMEM119 and P2RY12
mRNA did not differ between untreated microglia de-
rived from WM or GM. When treated with IFNγ+LPS
Fig. 4 Boxplot of semi-automatic quantification of the of the DAB stained area as percentage of the ROI. in the demyelinated center of lesions
compared to normal appearing matter. Boxplots represent the mean, the 1st and 4th quartile and the minimum and maximum value. Post-hoc
testing was done between WM groups and between GM groups. N = 15 for NAWM, N = 10 for active WML, N = 7 for chronic-active WML, N = 5
for leuko WML, N = 16 for NAGM, N = 8 for subpial GML, N = 5 for leuko GML. # = p = 0.07, * = p < 0.05, ** = p < 0.01, *** = p < 0.001
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or IL-4, primary human microglia derived from WM
and GM showed upregulation of P2RY12 expression
(WM: X2 = 10.9, df = 2, p < 0.01; GM: X2 = 12, df = 2, p <
0.01) while TMEM119 mRNA levels were only regulated
in microglia derived from the WM (X2 = 7.8, df = 2, p <
0.05). Post-hoc testing revealed that TMEM119 mRNA
was reduced after IL-4 treatment in WM-derived micro-
glia (p < 0.05) (Fig. 6). P2RY12 mRNA level was attenu-
ated after treatment with IFNγ+LPS in both WM- and
GM-derived microglia (WM: p < 0.05, GM: p < 0.05),
while after IL-4 treatment, P2RY12 expression was en-
hanced in the GM only (p < 0.05) (Fig. 6). However, it
must be noted that variation in P2RY12 and TMEM119
mRNA levels was high in all conditions studied (see Fig. 6).
Expression of AIF-1 (gene for Iba-1) did not differ be-
tween WM and GM derived microglia (Additional file 1:
Figure S3). In addition our microglial cultures were not
contaminated with astrocytes as shown by the lack of
amplification of GFAP (Additional file 1: Figure S3).
Microglia derived from both WM and GM showed down-
regulation of the anti-inflammatory marker mannose
receptor (MRC) after treatment with IFNγ+LPS and up-
regulation of the pro-inflammatory marker interleukin
(IL)-1β whereas treatment with IL-4 did not affect these
markers (Additional file 1: Figure S3) [11, 15, 18].
WMLs feature more infiltrated lymphocytes and
lymphocyte-secreted cytokines than subpial GMLs
Based on the observed regulation of TMEM119 and
P2RY12 in microglia by IFNγ+LPS and IL-4, we studied
the presence of lymphocytes that can produce IFNγ or
IL-4 in WMLs and GMLs. A cell count of CD3+ (T-
cells), CD20+ (B-cells), IL-4+ and IFNγ+ cells was con-
ducted in WMLs, GMLs, NAWM and NAGM (Table 4).
All immunohistochemical markers showed significance
at the group level (CD3: X2 = 37.06, p < 0.0001; CD20:
X2 = 11.26, p < 0.05; IL-4: X2 = 27.13, p < 0.0001; IFNγ:
X2 = 21.78, p < 0.0002). Subsequent post-hoc analysis re-
vealed that active WMLs had more CD3+ (p < 0.01) and
IFNγ + (p < 0.05) cells compared to NAWM while
chronic-active WMLs presented with more CD3+ (p <
0.01) and IL-4+cells (p < 0.05) (Fig. 7, Table 4). Although
Fig. 5 Representative images of immunoreactivity for MHC-II (a, b, c), Iba-1 (d, e, f), TMEM119 (g, h, i) and P2RY11 (j, k, l) along the rim of
various lesion types. Scalebar (a-l) = 50 μm
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CD20+ cell counts were significantly different at the
group level in the Kruskal-Wallis test pairwise compari-
sons, there was no significant difference between groups.
When comparing immunoreactivity present in GMLs
versus NAGM, no differences were found.
In addition, we studied whether the absence or pres-
ence of CD3+ and CD20+ cells in the meninges close to
the subpial GMLs is of relevance for TMEM119 and
P2RY12 immunoreactivity in subpial GMLs. We ob-
served that TMEM119 and P2RY12 immunoreactivity in
subpial GMLs was present irrespective of lymphocytes
being present in meninges close to the lesions (Fig. 8).
Discussion
The present study is the first to identify that in post-
mortem material for MS patients, immunoreactivity for
TMEM119 and P2RY12 in MS GMLs is different to that
in WMLs. The level of TMEM119 and P2RY12 immu-
noreactivity hardly changes in GMLs compared to
NAGM whereas clearly less immunoreactivity of both
homeostatic markers was observed in WMLs compared
to NAWM. Our subsequent in vitro observations of hu-
man microglia showed that TMEM119 and P2RY12
mRNA from WM and GM microglia is regulated by
IFNγ+LPS and IL-4. Subsequent analysis of lymphocyte
infiltration, and IFNγ and IL-4 immunoreactivity in le-
sions revealed lower presence of lymphocytes in GMLs
than in WMLs coinciding with less IFNγ and IL-4 im-
munoreactivity in GMLs. We conclude that the observed
difference in immunoreactivity for TMEM119 and
P2RY12 in GMLs and WMLs could be due to the ab-
sence or presence of lymphocytes and inflammatory me-
diators in the parenchyma.
Recently, TMEM119 and P2RY12 expression in the
brain is considered to represent microglia, maintaining
homeostasis of the CNS [11, 12, 30]. Contrary to Iba-1
and MHC-II, TMEM119 and P2RY12 are exclusively
expressed by microglia and not by infiltrated
Fig. 6 Graphs of TMEM119 and P2RY12 mRNA levels in cultured primary human microglia derived from WM enriched areas or GM enriched areas
treated with IFNγ+LPS or with IL-4 compared to untreated WM microglia. mRNA levels from GM derived cells are represented in the grey-
coloured box. Data are presented as individual patient-derived microglia measurements and means (bars). N = 10 for all WM-derived microglia
conditions, N = 7 for IL-4 treated GM-derived microglia N = 8 for IFNγ+LPS treated GM-derived microglia and N = 9 for untreated GM-derived
microglia. * = p < 0.05
Table 4 Distribution of CD3 (+), CD20 (+), IL-4 (+) and IFNγ (+) cells/mm2 in MS brain tissue
NAWM Active WML Chronic-active WML NAGM Subpial GML
CD3 2.0 ± 1.0 45.6 ± 14.5** 19.4 ± 4.2** 0.2 ± 0.1 0.7 ± 0.4
CD20 1.1 ± 0.4 4.3 ± 2.5 2.1 ± 0.6 0.4 ± 0.2 0.5 ± 0.3
IL-4 0.5 ± 0.4 1.1 ± 1.1 2.3 ± 0.6* 0.0 ± 0.0 0.0 ± 0.0
IFN-γ 0.2 ± 0.1 5.7 ± 2.8* 1.1 ± 0.5 0.0 ± 0.0 0.0 ± 0.0
Counts of CD3, CD20 and IL-4 (+) and IFNγ (+) cells in the NAWM (N = 18), active WMLs (N = 10), chronic-active WMLs (N = 7), NAGM (N = 15), subpial GMLs (N = 9).
Data is presented as mean +/− SEM
* = p < 0.05, ** < p < 0.01
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Fig. 7 Representative images of IFNγ and IL-4 immunoreactivity in active (a, b) and chronic-active WMLs (c, d), an active subpial GML (e, f) and
subpial GMLs (g, h). Scalebar (a-h) = 50 μm
Fig. 8 Representative images of CD3, CD20, TMEM119 and P2RY12 immunoreactivity in subpial GMLs showing meningeal infiltration and in
subpial GMLs without meningeal infiltration. In subpial lesions with infiltration of CD3+ cells (a) and CD20+ cells (b) show immunoreactivity for
TMEM119 (c) and P2RY12 (d). In subpial GMLs without infiltration of CD3+ (e) and CD20+ (f), immunoreactivity for TMEM119 (g) and P2RY12 (h)
is similar. Scalebar (a-h) = 100 μm. Inserts show magnifications of the area of interest. Scalebar inserts = 50 μm
van Wageningen et al. Acta Neuropathologica Communications           (2019) 7:206 Page 13 of 16
macrophages [11, 12, 35]. Therefore, in this study we uti-
lized TMEM119 and P2RY12 expression to study micro-
glia in WMLs and GMLs compared to normal appearing
matter. Whereas we observed that in (active) WMLs,
TMEM119 and P2RY12 immunoreactivity is largely absent
compared to NAWM, which is in line with previous find-
ings [16, 35], we now show that the level of TMEM119
and P2RY12 immunoreactivity is not affected in GMLs
compared to NAGM. To exclude the possibility that this
difference is due to distant locations of the lesions (cortical
GM compared to more inflammatory WM) or due to time
of development of the lesions (e.g. GML develop earlier on
in the disease and are therefore less inflammatory), we
verified and confirmed that in leukocortical (type 1) le-
sions, encompassing both WML and GML, this difference
in TMEM119 and P2RY12 immunoreactivity is also
present. In addition, preactive lesions in the white matter
show immunoreactivity for TMEM119 and P2RY12.
Whereas in the center of active WMLs TMEM119 and
P2RY12 immunoreactivity is absent, TMEM119+ micro-
glia are visible surrounding the lesion, and both
TMEM119+ and P2RY12+ microglia are visible in the
rim of chronic-active WMLs. These findings correspond
with previous observations that also showed microglial
TMEM119 and P2RY12 immunoreactivity along the
edge of (chronic-)active WMLs [15, 17]. Of interest is
that in a subpial GML with a clear rim of MHC-II+
microglial cells, we observed that these microglia are
TMEM119+ but not P2RY12+. This observation was
similar to what was seen in the edge of active WMLs.
However, immunologically active GMLs are rarely found
in post-mortem MS brain material and are mostly repre-
sented by leukocortical lesions [23]. Therefore, although
we cannot conclude that inflammation as seen in WMLs
is present in GMLs during ongoing MS, our data suggest
that the status and possible role of microglia along the
edge of demyelinating lesions might be similar in active
WMLs and active GMLs. In addition, we found that in
subpial GMLs, rod-shaped microglia were present which
were TMEM119+ and P2RY12+. Rod-shaped microglia
have been proposed to play a role in synaptic stripping,
representing neurodegeneration which is not necessarily
mediated by inflammation [36, 37], but is present in
various neurodegenerative diseases [38]. The presence of
rod-shaped microglia in GMLs suggests that these cells
are responsive irrespective of the relative absence of
lymphocytes, and low MHC-II immunoreactivity.
We subsequently questioned whether this different ex-
pression of TMEM119 and P2RY12 of microglia in the
center of GMLs versus WMLs could be explained by in-
trinsic differences in responsivity of WM and GM de-
rived microglia. Indeed, P2RY12 mRNA is reduced by
IFNγ+LPS in microglia from WM and GM. While
studying WM-derived microglia, others have shown
similar results upon IFNγ+LPS treatment, but also in-
creased expression upon IL-4 treatment which we ob-
served to be significantly altered in GM-derived microglia
only [15, 18]. As we are not aware of any other observa-
tions on TMEM119 regulation in human microglia
in vitro, we are the first to find that IL-4 treatment signifi-
cantly reduced its mRNA level in WM-derived microglia.
Moreover, there is a clear tendency that IFNγ+LPS re-
duces TMEM119 expression in microglia from both ori-
gins. Therefore, it seems that, in general, microglia
derived from human WM or GM can change expression
of TMEM119 or P2RY12 upon exposure to inflammatory
mediators, although not entirely in a similar fashion.
Based on these in vitro observations, we next explored
the possibility that the presence of IL-4 and IFNγ immu-
noreactivity varies between GMLs and WMLs, which
would affect microglial expression of TMEM119 and
P2RY12 in both lesion types. As shown in active WMLs,
more IFNγ+ cells were found compared to the other lesion
subtypes or normal-appearing matter while in chronic-
active WMLs more IL-4+ cells were observed, but in
GMLs no IL-4 or IFNγ positive cells were found. This ob-
servation is in line with our observed increased infiltration
of CD3+ T-cells and CD20+ B-cells in WMLs which were
relatively absent in subpial GMLs similar to as was shown
before [22, 23]. Even in subpial GMLs close to meninges
containing infiltrated CD3+ and CD20+ cells, we did not
observe a difference in the level of immunoreactivity for
TMEM119 and P2RY12. This indicates that, although re-
cent evidence points to a role for meningeal infiltration in
neuronal loss and glial activation status in MS cortex [5],
microglial homeostatic status as indicated by expression
of TMEM119 and P2RY12 in demyelinated subpial GM is
not altered by the presence of meningeal lymphocytes and
still ongoing meningeal inflammation.
The observation that P2RY12 and TMEM119 immuno-
reactivity is downregulated in MS WMLs and not in
GMLs raises the question as to whether that has func-
tional consequences. The ligand for P2RY12 is Adenosine
diphosphate (ADP) [18] and it has been proposed that
P2RY12 is involved in microglial process motility in the
response of the CNS to injury [39] and upon damage to
the blood-brain barrier [40]. Downregulation of P2RY12
would suggest down-tuning of microglial involvement in
injury-related processes. TMEM119 was originally re-
ported to be expressed in the plasma membrane of mouse
osteoblasts and later found to be expressed in human
bone tissue, dendritic cells and lymphoid tissues [16]. The
presence of TMEM119 in osteosarcoma cells is related to
cell invasion and migration [41], yet its function in micro-
glia remains unknown. The recent development of micro-
glia specific TMEM119 knock-in and CreERT2 mice [28]
will be a useful tool to gain more knowledge on the func-
tional role of TMEM119.
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Thus, in conclusion, these data suggest that the con-
tinued presence of TMEM119 and P2RY12 immunore-
activity in subpial GMLs could reflect the absence of IL-
4 and IFNγ and low presence of infiltrating lymphocytes
in the lesion parenchyma (and not meninges) compared
to WMLs. However, in subpial GMLs, where lympho-
cytes are absent from the lesion parenchyma and
TMEM119 and P2RY12 immunoreactivity is therefore
still present, TMEM119 and P2RY12 immunoreactivity
is observed in rod-like microglia, showing a response of
homeostatic microglia to demyelination in these lesions.
Furthermore, immunoreactivity for TMEM119 and
P2RY12 is observed in preactive lesions in the NAWM
as well as along the edge of active WMLs and GML.
Though it is plausible that differences in microglial re-
sponse in WMLs and GMLs could be due to a difference
in time of lesion development, analysis of TMEM119
and P2RY12 immunoreactivity in leukocortical lesions
spanning both WM and GM reveal a similar pattern of
immunoreactivity as WMLs and subpial GMLs. It is
therefore plausible that blocking the entrance of lym-
phocytes into the CNS of MS patients may not interfere
with all possible effects of microglia in both WMLs and
GMLs.
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